Ayble Health, an AI-enabled virtual clinic for gastrointestinal (GI) and autoimmune conditions, has raised $16 million in Series A funding.
The oversubscribed round was led by Neon, with participation from Unum Ventures, Upfront Ventures, M13, Cleveland Clinic Ventures, DigiTx, Accomplice, and strategic investors. The funding brings Ayble’s total capital raised to more than $27 million.
Ayble will use the funding to advance its AI and clinician-led precision care model and expand its services beyond gastrointestinal conditions into other complex therapeutic areas, starting with autoimmune diseases.
“I built Ayble because I’m an Inflammatory Bowel Disease patient,” said Sam Jactel, Founder and CEO of Ayble Health. “I’ve lived through the diagnostic delays, the care gaps, and the overall frustration of a system that isn’t designed for patients who need ongoing, coordinated care. Many patients are also managing autoimmune conditions, and too often, no one is treating the whole picture. This funding lets us close that gap: deepening our AI precision care capabilities and extending our multidisciplinary model into autoimmune, so patients get one team built for how these conditions actually show up in their lives. The growth we’ve seen and the partnerships we’ve built with leading employers, payers and providers demonstrates the need for our work is massive.”
The company combines GI-trained doctors, dietitians, behavioral health specialists, pharmacists, health coaches, and care coordinators with AI-powered technology.
“I’ve been tracking the GI space closely for years, and what Ayble has built is different,” said Kimmy Scotti, Founding and Managing Partner at Neon, who previously co-founded 8VC, “Having invested early in top digital health companies, I’ve seen what it takes to build a category-defining company in healthcare. Ayble has spent years building the clinical evidence before they scaled the business. That earns trust from the full ecosystem: health systems, payers, and most importantly, patients, and it’s what makes a durable market leader.”
Ayble currently covers more than 80 million Americans through partnerships with health plans, employers, and health systems. The company says its care model has been supported by 16+ peer-reviewed studies and has helped patients achieve an average 47% improvement in GI symptoms.
